MedWatch

ALK rival does not venture into new business segment

French drug group Stallergenes Greer maintains its strategy of growing its core business, while the rival ALK launches new consumer care division. "We will continue to build on our strengths," says the Stallergenes CEO.

Fereydoun Firouz has served as CEO and chairman in Stallergenes Greer for four years. After new year, he hands over both positions to new resources. | Foto: Stallergenes Greer

The global allergy market is mainly divided between two actors - Danish ALK and French Stallergenes Greer.

The companies compete for the same customers, and they both concentrate their efforts on immunotherapeutic tablet vaccines against allergy in addition to allergy drops.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier